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Abstract
Background: Individuals with substance-use disorders exhibit emotional problems, including deficits in emotion recognition 
and processing, and this class of disorders also has been linked to deficits in dopaminergic markers in the brain. Because 
associations between these phenomena have not been explored, we compared a group of recently abstinent methamphetamine-
dependent individuals (n = 23) with a healthy-control group (n = 17) on dopamine D2-type receptor availability, measured 
using positron emission tomography with [18F]fallypride.
Methods: The anterior cingulate and anterior insular cortices were selected as the brain regions of interest, because 
they receive dopaminergic innervation and are thought to be involved in emotion awareness and processing. The 
Toronto Alexithymia Scale, which includes items that assess difficulty in identifying and describing feelings as well 
as externally oriented thinking, was administered, and the scores were tested for association with D2-type receptor 
availability.
Results: Relative to controls, methamphetamine-dependent individuals showed higher alexithymia scores, reporting 
difficulty in identifying feelings. The groups did not differ in D2-type receptor availability in the anterior cingulate or anterior 
insular cortices, but a significant interaction between group and D2-type receptor availability in both regions, on self-report 
score, reflected significant positive correlations in the control group (higher receptor availability linked to higher alexithymia) 
but nonsignificant, negative correlations (lower receptor availability linked to higher alexithymia) in methamphetamine-
dependent subjects.
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Conclusions: The results suggest that neurotransmission through D2-type receptors in the anterior cingulate and anterior 
insular cortices influences capacity of emotion processing in healthy people but that this association is absent in individuals 
with methamphetamine dependence.
Keywords: Methamphetamine dependence, emotion processing, alexithymia, dopamine, PET
Introduction
Individuals with substance use disorders exhibit emotional 
problems, including impaired emotional awareness (Goldstein 
et  al., 2009; Fernández-Serrano et  al., 2010) and alexithymia, 
which is considered to be a set of trait-like deficits in emotion 
processing (Rybakowski et al., 1988; G. J. Taylor et al., 1990; Pinard 
et  al., 1996; de Haan et  al., 2014). Features of alexithymia are 
thought to influence the emotional disposition to substance use 
(Bonnet et al., 2013), possibly with substance abuse serving as a 
self-medication for alexithymia (G. J. Taylor et al., 1999). Helping 
to clarify the neurobiological basis of abnormalities in emotion 
processing associated with substance use disorders, therefore, 
ultimately may contribute to improved treatment strategies for 
individuals with these individuals.
Neuroimaging findings provide evidence that the combined 
action of the anterior cingulate cortex (ACC) and the anterior 
insular cortex (AIC) contributes to a facet of emotion process-
ing associated with alexithymia. Those regions are conjointly 
activated in paradigms involving emotion processing (Medford 
and Critchley, 2010). Change in cerebral blood flow induced in 
ACC by presentation of exteroceptively and interoceptively 
emotional cues, and assessed using positron emission tomog-
raphy (PET), is positively correlated with scores on the Levels 
of Emotional Awareness Scale (Lane et  al., 1998; McRae et  al., 
2008), and the capacity for emotional experience (Schafer et al., 
2007) is blunted in patients with traumatic injury or cerebro-
vascular insults in the frontal cortex, including ACC. Functional 
magnetic resonance imaging (fMRI) has been used to show AIC 
activation when subjects reexperience emotions by recalling 
personal emotional experiences (Damasio et al., 2000) and that 
self-reports of alexithymia and empathy are associated with 
activation in the AIC induced by viewing pleasant and unpleas-
ant pictures (Silani et al., 2008). Studies of brain structure have 
shown an association of alexithymia with smaller gray-matter 
volume in the ACC and AIC (Borsci et al., 2009; Grabe et al., 2014) 
and associations of cingulate-cortex and posterior-insula vol-
umes with cognitive and affective dimensions of alexithymia 
(Goerlich-Dobre et al., 2014).
Individuals who have low emotional clarity, a latent con-
struct of alexithymia, perform worse in tests of several 
executive domains, including self-monitoring and error recog-
nition, than subjects with greater emotional clarity (Koven and 
Thomas, 2010). Therefore, impaired emotional processing and 
error monitoring would be expected to have some commonal-
ity in neuroanatomical substrates. ACC and AIC are key regions 
contributing to emotional awareness as well as sensitivity to 
errors in research participants with addictions (for review, see 
Goldstein et al., 2009; Moeller and Goldstein, 2014). In one fMRI 
study, blunted sensitivity to punishment in a go/no-go task was 
associated with less activation in ACC and right AIC of cocaine 
users than in healthy controls (Hester et  al., 2013). Cocaine 
users have less capacity for inhibitory control and reduced 
error awareness than healthy-control subjects, as well as less 
task-related fMRI activity elicited in these regions by a go/no-go 
task (Kaufman et al., 2003; Hester et al., 2007). Notably, however, 
reduction in task-related ACC activity during an inhibitory-con-
trol task was greater in cocaine users who had impaired insight 
than in those without the impairment (Moeller et  al., 2014). 
Moreover, a recent fMRI study demonstrated that intramodule 
connectivity in the salience network, including ACC and AIC, is 
negatively related to the Difficulty Describing Feeling scale in 
TAS-20 in cocaine users (Liang et al., 2015).
Methamphetamine (MA) use disorder (ie, amphetamine-type 
substance use disorder, DSM-5) represents a substantial world-
wide public health problem (Rawson, 2013). Compared with 
healthy controls, MA-dependent subjects exhibit structural and 
functional abnormalities in the ACC and insula (London et al., 
2004; Morales et al., 2012; Gowin et al., 2013) and evidence of defi-
cits in central dopaminergic transmission (Chang et al., 2007). As 
postmortem studies of the human brain have shown dopamin-
ergic projections to the ACC and insula and D2-type receptors in 
ACC and insula (Gaspar et al., 1989; Hall et al., 1996), it is plausi-
ble that dopaminergic dysfunction linked to MA use is linked to 
emotional-processing deficits associated with alexithymia. This 
view is supported by a high incidence of alexithymia in patients 
with neurological diseases that feature dopaminergic dysfunc-
tion, such as Parkinson’s disease (Costa et al., 2010).
In prior studies comparing MA-dependent subjects and 
healthy-control subjects, the MA group exhibited higher scores 
on one TAS-20 subscale, which indexes difficulty in identifying 
feelings (Payer et al., 2011). MA-dependent subjects also show 
lower striatal dopamine D2-type receptor availability (Volkow 
et  al., 2001; B.  Lee et  al., 2009), raising the possibility that the 
two phenomena are related. Nonetheless, the role of dopamin-
ergic signaling in emotion identification or processing had not 
been definitively tested in healthy control subjects or in those 
with addictions. We therefore tested the relationship between 
emotion processing, as measured by self-report on the TAS-20, 
and dopamine D2-type receptor availability in the ACC and AIC, 
comparing healthy control with MA-dependent participants 
using PET with [18F]fallypride, a radiotracer with sufficient affin-
ity for D2-type receptors to allow measurement in extrastriatal 
regions (Mukherjee et al., 1995; Mukherjee et al., 2002).
Methods
Participants
All procedures were approved by the University of California Los 
Angeles (UCLA) Office for the Protection of Research Subjects. 
Participants, 18 to 55  years of age were healthy volunteers or 
individuals with MA dependence who were not seeking treat-
ment. They were recruited using Internet and local newspa-
per advertisements, were assigned to 2 groups (control and 
MA), and received a detailed description of the study protocol. 
All participants provided written informed consent. The sam-
ple studied here overlaps with a previous study of dopamine 
D2-type receptors and impulsiveness (16 of 17 controls and 16 of 
23 MA-group participants in this study) (B. Lee et al., 2009) and 
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another previous study of affect processing in MA-dependent 
individuals, in which the TAS-20 scale was administered (15 of 
17 controls and 20 of 23 MA-group participants in this study) 
(Payer et al., 2011).
Eligibility was determined using questionnaires, including 
the Structured Clinical Interview for DSM-IV Axis-I Disorders, 
to determine psychiatric diagnoses and a medical examination. 
Inclusion criteria for the MA group were current MA depend-
ence, as indicated by DSM-IV criteria, and a positive urine test 
for MA at entry to the study. Exclusion criteria were any cur-
rent Axis-I diagnosis (other than MA dependence or substance-
induced mood or anxiety disorder in the MA group, or nicotine 
dependence in either group); use of psychotropic medications 
or illicit drugs other than MA or nicotine as indicated above, 
although light use of marijuana and alcohol was allowed (see 
below); central nervous system, cardiovascular, pulmonary, or 
systemic disease; human immunodeficiency virus seropositive 
status; severe hepatic impairment; chronic inflammation; preg-
nancy; and lack of English fluency. Use of marijuana or alcohol 
was allowed in both groups as long as it was below the threshold 
for a diagnosis of abuse or dependence as defined by DSM-IV.
All of the MA group participants were admitted to the UCLA 
General Clinical Research Center, where they maintained absti-
nence from MA and other drugs of abuse other than nicotine (in 
cigarettes) and caffeine (in beverages), as verified by urine screen-
ing. The control group participants were asked to visit the research 
sites on different days for psychological testing and imaging. On 
the days when brain-imaging or self-report data on the TAS-20 
were collected, participants also provided urine samples negative 
for MA and other drugs. On completion of the study, participants 
were compensated with cash, gift certificates, and vouchers.
MRI and PET Imaging
Structural MRI scans were acquired on a 1.5-T Siemens Sonata 
tomograph for coregistration with PET images to define volumes 
of interest (VOI) (described below). A  high-resolution sagittal 
T1-weighted 3D volumetric scan was acquired using a whole-
brain magnetization-prepared rapid acquisition with gradient 
echo sequence (TR = 1900 ms, TE = 4.38 ms, flip angle = 15, field of 
view = 256 × 256 × 160, 160 slices, thickness = 1 mm).
PET scans were acquired using [18F]fallypride. The tomo-
graph, a Siemens ECAT EXACT HR+ scanner, has an in-plane res-
olution full-width at half-maximum of 4.6 mm, axial resolution 
full-width at half-maximum of 3.5 mm, and axial field of view of 
15.52 cm in the 3-dimensional scanning mode. Participants were 
placed in the supine position, and their heads were immobilized 
using a thermoplastic mask that was marked for repositioning. 
A transmission scan for attenuation correction was conducted 
using a rotating 68Ga/68Ge rod source. Emission data were col-
lected for 80 minutes after the radiotracer injection. Participants 
then were removed from the scanner for a 20-minute break, 
during which they were instructed to void their bladders to 
reduce radiation exposure. They returned to the scanner and 
were repositioned. After another transmission scan, additional 
emission data were collected for an 80-minute period to achieve 
the 180-minute scan duration required for an accurate meas-
urement of binding potential using [18F]fallypride (details in PET 
data processing) (Vernaleken et al., 2011).
Self-Report Assessment
Capacity for emotional processing was assessed using the TAS-
20 (Bagby et al., 1994), a widely used questionnaire that has been 
validated for testing of substance abusers (Cleland et al., 2005). 
The TAS-20 consists of 3 subscales that provide scores for cor-
responding factors: factor 1: difficulty identifying feelings; factor 
2: difficulty describing feelings; and factor 3: externally oriented 
thinking. TAS-20 total score (the sum of the 3 subscale scores) 
is interpreted as follows: 0 to 51: no alexithymia; 52 to 60: pos-
sible alexithymia; 61 and higher: alexithymia (G. J. Taylor et al., 
1999). The Beck Depression Inventory (BDI) (Beck et al., 1996) was 
administered to verify depressive symptoms and potentially 
control for its confounding effects on TAS-20 scores because 
of indications that depression contributes to TAS-20 score 
(Honkalampi et al., 2000).
PET Data Processing
Reconstructed PET data were combined into 16 images, each 
reflecting data averaged over 10 minutes. FSL MCFLIRT (FMRIB 
Centre, Department of Clinical Neurology, University of Oxford, 
Oxford, UK) was used to correct for head motion. The PET images 
were coregistered to the structural MRI images using a 6-param-
eter, rigid-body spatial transformation (FSL FLIRT [Jenkinson 
et  al., 2002]). A  single VOI, defining ACC bilaterally in Montreal 
Neurological Institute (MNI) space, was based on the Harvard-
Oxford Atlas. Separate VOIs for the anterior insulae were defined 
in MNI space using the definition specified by the functional con-
nectivity analyses of Deen et al. (2011). These VOIs were trans-
formed to native space using FSL FNIRT. The primary regions 
investigated were the ACC and AIC because of their known roles 
in emotional self-awareness, but adhoc exploratory analysis was 
performed on the other regions, which have relatively high den-
sities of dopamine D2-type receptors, including amygdala, hip-
pocampus, globus pallidus, thalamus, and striatum. Bilateral VOIs 
for the exploratory regions were anatomically defined on each 
participant’s MRI images using auto-segmentation procedures in 
FSL FIRST software (Patenaude et al., 2011). Cerebellar VOIs were 
manually drawn on both hemispheres in MNI space, then trans-
formed to native space. Striatum (caudate and putamen) and cer-
ebellum VOIs were used in PET modeling (see below).
Time-activity data were extracted from motion-corrected, 
coregistered PET data and imported into PMOD Kinetic Modeling 
(PMOD Technologies Ltd., Zurich, Switzerland). Time-activity 
curves were first fit for the striatum, which has a high density 
of D2-type receptors. The simplified reference tissue model 
(Lammertsma and Hume, 1996) was used to provide an estimate 
of the rate constant k2´ for the transfer of the radiotracer from 
the reference-region tissue compartment to the plasma. The 
cerebellum was used as the reference region because of its low 
specific binding for [18F]fallypride (Mukherjee et  al., 2002). The 
VOI time-activity curves were refit using the simplified refer-
ence tissue model 2 model (Wu and Carson, 2002) using PMOD 
Kinetic Modeling, with the k2´value derived from the striatum 
applied to all VOIs. Binding potential (BPnd), an index of receptor 
availability, was then calculated as R1*k2´/k2a –1, where R1 = K1/
K1´ is the ratio of tracer-delivery parameters from plasma to the 
target region and reference region, and k2a is the single-com-
partment rate constant for transfer from the target-region tissue 
compartment to plasma.
Statistical Analysis
Group differences in age, education, BDI, and TAS-20 scores were 
tested by unpaired Student’s t tests, and group differences in 
sex and smoking status were evaluated by Fisher’s exact test. 
Group differences in BPnd were tested by ANCOVA, controlling 
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for age, sex, and smoking status, because of strong evidence for 
age-related decline of D2-type receptors in brain (Rinne et al., 
1993; Kaasinen et al., 2000), for a sex difference in D2-type BPnd 
in cortical regions (Kaasinen et al., 2001) and for lower striatal 
D2-type BPnd among smokers than nonsmokers (Fehr et  al., 
2008; Brown et  al., 2012). The interaction between group and 
BPnd on emotional self-awareness was tested using ANCOVA, 
with TAS-20 total score as the dependent variable and age, sex, 
smoking status, the interval (in days) between the PET scan and 
TAS-20 assessment (which was not balanced between groups; 
see Results), subject group, BPnd, and the interaction of group 
and BPnd as the independent variables. Relationships between 
the TAS-20 scores and D2-type BPnd were tested using partial 
correlations controlling for age, sex, smoking status, and the 
interval between PET and TAS-20 assessment for the reasons 
given above. The criterion for statistical significance was P < .05, 
2-tailed. All statistical analyses were conducted using SPSS IBM 
19 (IBM, Armonk, NY).
Results
Participants
Forty participants were recruited and assigned to a control 
group (n = 17) and a MA group (n = 23). The groups did not dif-
fer significantly in age or in sex distribution (Table 1). The con-
trol group included almost equal numbers of men and women, 
whereas there were twice as many men as women in the MA 
group. Cigarette smokers were more prevalent in the MA group. 
MA group participants reported using MA for 10.4  years (SD: 
7.33; range: 2–24) and age of first MA use at 22.8 years (SD: 7.43; 
range: 13–38) and were abstinent from MA for 7.2 days (SD: 3.11; 
range: 4–15) before PET scanning and for 8.0  days (SD: 2.91; 
range: 4–17) before administration of the TAS-20. MA-group 
participants reported having used MA for 20.2  days (SD: 7.48; 
range: 5–30) in the month before entering the study, and the 
mean amount of MA use in the week before enrolling the study 
was 2.90 g (SD: 3.36; range: 0–14.5). Fourteen MA group partici-
pants but none of the control subjects reported marijuana use 
within 1 month of entering the study, reporting use for 0.6 days 
(SD: 1.09; range: 0–4) in the last month. Due to scheduling needs 
of the participants and the imaging facility, the TAS-20 admin-
istrations and PET scans were conducted on different days. 
The interval between the PET scan and TAS-20 administration 
was 1.8  days on average for the MA group participants and 
significantly longer for the control group (32.5 days; unpaired 
Student’s t tests P < .001).
Self-Report Assessments
All control group participants and all but 5 of the MA group 
participants gave TAS-20 total scores consistent with no alex-
ithymia (ie, ≤51); the remaining 5 MA group participants met 
the criteria for possible alexithymia. TAS-20 total scores were 
significantly lower for the control group than the MA group (t 
38 = -2.268, P = .03), with significantly lower scores for factor 1: dif-
ficulty identifying feelings (t 35.884 = -3.255, P = .003: equal variances 
not assumed), but not for either of the other 2 factors (factor 2: t 
38 = -1.177, P = .25; factor 3: t 38 = -1.109, P = .27) (Table 1), consistent 
with the findings obtained with the larger sample from which 
these participants were drawn (Payer et al., 2011).
The TAS-20 total score was not significantly correlated with 
BDI score (r = -0.093, P = .57 by Pearson’s correlation). The mean 
BDI scores, obtained close to the time of TAS-20 measurement, 
were 3.65 (SD: 3.90) and 6.09 (SD: 3.65) for the control and MA 
groups, respectively, and did not differ significantly between 
groups (t 38 = -1.534, P = .133).
Dopamine D2-Type Receptor Availability and 
Association with TAS-20 Total Score
In all analyses, left and right AIC VOI data were volume-weight 
averaged, because they were strongly correlated (r = 0.884, P < 
.001 by Pearson’s correlation). There was no significant group 
difference in BPnd in the ACC (control: 0.53 [SD: 0.13]; MA: 0.51 
[SD: 0.13]; F1, 35 = 0.136, P = .715), AIC (control: 0.75 [SD: 0.15]; MA: 
0.69 [SD: 0.19]; F1, 35 = 1.616, P = .21), or other regions tested except 
for the striatum. In the striatum, the control group had a signifi-
cantly higher BPnd than the MA group (control: 16.32 [SD: 1.80]; 
MA: 14.99 [SD: 1.87]; F1, 35 = 5.405, P = .03).
Taking TAS-20 total score as the dependent variable in the 
ANCOVA, there was a significant interaction between group (con-
trol vs MA) and BPnd in both the ACC (F1, 31 = 9.716, P = .004) and 
AIC (F1, 31 = 5.508, P = .03) (Figure 1; Table 2). For the control group, 
significant positive partial correlations were found between TAS-
20 total score and BPnd in both the ACC (r = 0.626, P = .02) and AIC 
(r = 0.619, P = .02), with these effects retaining significance after 
Bonferroni correction for multiple comparisons (ie, for the 2 
VOIs). In the MA group, D2-type BPnd in the ACC (r = -0.302, P = .21) 
and AIC (r = -0.075, P = .76) showed nonsignificant negative partial 
Table 1. Demographic and Psychological Measures of Research Participants
Control Group (n = 17) MA groupa (n = 23) Group difference: P value
Age (years) 32.1 (7.60) 35.6 (9.12) 0.21 b
Sex (male/female) 9/8 15/8 0.52 c
Education (years) 13.4 (1.75) 12.2 (3.42) 0.23 b
Cigarette smokers 5 20 < 0.001 c
TAS-20 total score 32.41 (8.27) 39.79 (10.32) 0.02 b
 Factor 1: Difficulty Identifying Feelings 7.94 (1.20) 11.30 (4.53) 0.01 b
 Factor 2: Difficulty Describing Feelings 8.24 (3.78) 10.42 (5.45) 0.20 b
 Factor 3: Externally Oriented Thinking 16.24 (5.08) 18.08 (5.20) 0.16 b
BDI 3.65 (3.90) 6.09 (5.62) 0.13 b
Abbreviations: BDI, Beck Depression Inventory; TAS-20, 20-item Toronto Alexithymia Scale.
All data are shown as means (SD).
aMA use: age of first use was 22.8 (7.43); 20.2 (7.48) days of use in month before enrolling in study; 2.90 (3.36) g used in week before enrolling.
bGroup difference evaluated by unpaired Student’s t test.
cGroup difference in distribution evaluated by Fisher’s exact test.
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correlations with the TAS-20 total score. Exploratory analyses of 
additional VOIs, with the TAS-20 total score as the dependent 
variable in ANOVA, indicated insignificant interactions between 
group and BPnd in the amygdala (F1, 31 = 2.950, P = .09), hippocam-
pus (F1, 31 = 2.060, P = .16), globus pallidus (F1, 31 = 2.703, P = .11), thala-
mus (F1, 31 = 2.910, P = .10), and striatum (F1, 31 = 3.042, P = .09) (Table 2). 
Partial correlations between BPnd and the TAS-20 score were in 
the same directions as in primary regions: positive in the control 
group and negative in the MA group, although those correlations 
did not reach significance.
Discussion
The goal of this study was to determine whether dopamine 
D2-type receptors are involved in the processing of emotion and 
whether they may play a different role in MA-dependent indi-
viduals compared with healthy controls. The focus was on the 
ACC and AIC, which have been linked to emotion processing and 
awareness of internal states (Critchley et al., 2004; Silani et al., 
2008; Medford and Critchley, 2010) and which also show struc-
tural and functional deficits in individuals with MA use disorder 
(London et al., 2004; Morales et al., 2012; Gowin et al., 2013). A sig-
nificant group difference in D2-type receptor availability, control 
group > MA group, was found in striatum in agreement with 
previous studies (Volkow et al., 2001; B. Lee et al., 2009) but not 
in any other regions tested, including ACC and AIC. While posi-
tive associations of D2-type receptor availability in ACC and AIC 
with the TAS-20 total score were observed for healthy control 
subjects, this relationship was not found among MA-dependent 
subjects, who exhibited higher TAS-20 total scores than control 
subjects. These findings suggest a difference in the contribu-
tions of dopaminergic transmission through D2-type receptors 
to the capacity of MA-dependent subjects in early abstinence to 
process feelings.
Figure 1. D2-type receptor binding potential (BPnd) and association with Toronto Alexithymia Scale (TAS-20) total score. (a) Volumes of interest (VOIs) of the anterior 
cingulate cortex (ACC), anterior insular cortex (AIC), and striatum are shown on an averaged BPnd map of the control group (n = 17). VOIs outlined in white. MNI coordi-
nates: x = 90, y = 135, z = 75 (mm). (b) Scatterplots showing individual data for the TAS-20 total score and BPnd in ACC and AIC. Blue circles represent data from individual 
participants in the control group, and red circles represent data from the MA group. BPnd was corrected for age, sex, smoking. Partial correlation analysis was used to 
determine r-values (*P < .05, NS nonsignificant, with P values not corrected for multiple-region comparisons).
Table 2. Association of Dopamine D2-type BPnd with the TAS-20 Total Score
Group-by-BPnd Interaction: P value
Correlation Coefficients
Control Group (n = 17) MA Group (n = 23)
ACC 0.004 a 0.626 b -0.302
AIC 0.03 a 0.619 b -0.075
Amygdala 0.08 0.191 -0.335
Hippocampus 0.11 0.276 -0.400
Globus pallidus 0.07 0.536 -0.269
Thalamus 0.09 0.410 -0.264
Striatum 0.09 0.307 -0.191
Abbreviations: ACC, anterior cingulate cortex; AIC, anterior insular cortex; TAS-20, the 20-item of Toronto Alexithymia Scale.
The P values shown are not corrected for multiple comparisons (ie, tests in 2 regions: ACC and AIC).
aSignificant interaction by ANCOVA controlling for age, sex, smoking status, and days of interval between PET and TAS-20.
bSignificant correlation by partial correlation analysis, controlling for age, sex, smoking status, and days of interval between PET and TAS-20.
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The positive relationship between D2-type BPnd and TAS-20 
score in healthy subjects, implying that high receptor availabil-
ity is associated with problems in emotion processing, is not 
immediately consistent with a report that L-dopa administra-
tion improves emotion perception in patients with Parkinson’s 
disease (Fleury et al., 2014). This pharmacological finding sug-
gests that in individuals with impaired dopaminergic neuro-
transmission, such as the MA-dependent subjects in our study, 
dopamine-enhancing interventions may help ameliorate defi-
cits in emotion processing associated with identifying/describ-
ing feelings. On the other hand, if one considers D2-type BPnd 
as a neurochemical marker of potential for signaling through 
D2-type receptors, it would appear that high levels of D2-type 
BPnd contribute to alexithymia and less capacity for process-
ing emotion. It is possible that optimal capacity for emotion 
processing is conferred by an optimal level of signaling through 
D2-type dopamine receptors in ACC and AIC, with exceedingly 
high levels linked to problems with emotion regulation. As none 
of the control participants met the criteria for alexithymia, how-
ever, the relationship may simply reflect a physiological correla-
tion within the range of normality.
Given the lack of group differences in D2-type BPnd in the 
cortical regions assayed and the fact that the effects of MA 
use are not limited to the dopamine system, a disruption in 
the association of D2-type receptors with the TAS-20 score 
can reflect effects on other neurotransmitter systems, such 
as the GABAergic and glutamatergic systems, which interact 
with dopamine D2-type signaling (Jayanthi et al., 2004, 2014). 
As positive associations of both GABA and glutamate concen-
trations in both the ACC and left AIC with the TAS-20 score 
have been observed (Ernst et  al., 2014), MA effects on these 
neurotransmitter systems may contribute to the observations 
made here.
The lack of association between D2-type BPnd and the TAS-20 
score in MA-dependent subjects stands in contrast to observa-
tion of an inverse association between intramodule connectivity 
in the salience-network with the Difficulty Describing Feelings 
subscale score on the TAS-20 in cocaine-dependent individuals 
but not healthy controls (Liang et al., 2015). Obvious differences 
between the studies are the type of stimulant and the fact that 
the primary self-report measure in the present study was the 
TAS-20 total score and not the Difficulty Describing Feeling sub-
scale. In addition, the cocaine users were not required to main-
tain abstinence for several days prior to testing, and almost 
one-half of the cocaine group subjects had positive urine tests 
for cocaine on the testing day, whereas the MA-dependent sub-
jects maintained supervised abstinence from all illicit drugs 
of abuse and alcohol for at least 4 days prior to testing. Aside 
from differences in potential effects of residual drug directly on 
behavior, there also might have been difference in the state of 
withdrawal in the two studies. Whether TAS-20 scores in this 
study were affected by acute withdrawal needs to be considered. 
Nevertheless, the TAS-20 score has been shown to be robust to 
substance withdrawal, especially for individuals without clini-
cally significant alexithymia (de Haan et  al., 2014). MA group 
participants actually were abstinent from MA for 8.0  days on 
average when the TAS-20 was administered; acute withdrawal 
symptoms from MA usually resolve within 1 week of initiating 
drug abstinence (Zorick et al., 2010). Nonetheless, future studies 
are warranted to determine how associations between D2-type 
receptor BPnd and measures of emotion processing vary with 
time of abstinence from MA.
There are limitations to this study, one of which is that TAS-
20 scores were relatively low compared with those in previous 
studies (Saladin et al., 2012; Ernst et al., 2014), and most of the 
participants did not meet the criterion for clinical alexithymia. 
The range in TAS-20 scores, however, was similar to that in a 
previous study showing a correlation between a neurochemi-
cal marker and the TAS-20 total score (Ernst et  al., 2014). In 
addition, for logistical reasons, there were some gaps in time 
between the self-report and PET measures, which ideally would 
have been collected on the same day. However, the time interval 
was controlled for statistically; and given the temporal stability 
of TAS-20 (Tolmunen et al., 2011), it is likely that this limitation 
is minimal. Another limitation is the small number of partici-
pants; necessitating the replication of our findings in a larger 
sample to demonstrate its reproducibility.
Finally, there are limitations associated with the use of [18F]
fallypride and PET. Although [18F]fallypride has sufficient affinity 
for dopamine D2-type receptors to allow measurement in stria-
tum and extrastriatal regions (Mukherjee et al., 2002), it does not 
distinguish between D2 and D3 receptor subtypes and does not 
resolve binding to receptors in different compartments, such as 
pre- vs postsynaptic receptors on different cellular elements in 
a region. Another factor to consider is that receptor availabil-
ity, measured by BPnd, represents the receptor pool accessible 
to radiotracer, and as such it can be influenced by both recep-
tor density and the concentration of intrasynaptic endogenous 
dopamine (Ito et  al., 2011). Indeed, [18F]fallypride binding in 
human cortex is responsive to change in intrasynaptic dopamine 
level induced by administration of amphetamine (Riccardi et al., 
2006; Cropley et al., 2008). However, on the basis of observations 
on the effect of dopamine depletion with α-methyltyrosine on 
the binding of [11C]raclopride, another D2-type receptor ligand 
(Martinez et  al., 2009), the extent to which BPnd measured 
using this tracer would be affected by individual differences in 
intrasynaptic dopamine in the absence of a challenge would be 
expected to be small.
Despite these limitations, this study is the first to suggest 
a role of dopaminergic neurotransmission through D2-type 
receptors in capacity for identifying/describing feelings and to 
show that this relationship is disrupted in individuals with MA 
dependence. It has been hypothesized that substance-depend-
ent individuals use drugs in an attempt to medicate themselves 
for unpleasant emotional states, which may be experienced as 
overwhelming due to impaired capacity to identify emotions 
(Khantzian, 1985). To the extent that this assertion is correct, 
further studies are warranted to help clarify the neurobiological 
basis for the problems in emotional processing in individuals 
with MA-related and other substance use disorders.
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